INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, August 4
28 juil. 2021 16h05 HE
|
INmune Bio, Inc.
Management to host conference call at 4:30 pm ET on that day BOCA RATON, Florida, July 28, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology...
INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease Clinical Trial and New Phase 1b AD Biomarker Data
26 juil. 2021 08h30 HE
|
INmune Bio, Inc.
Phase 2 study of XProTM will be a six-month, blinded, randomized, placebo-controlled trial in 168 patients with mild Alzheimer’s disease and biomarkers of inflammation. Additional analysis...
INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer’s Association International Conference 2021
19 juil. 2021 08h30 HE
|
INmune Bio, Inc.
Company to introduce design of upcoming Phase 2 study of XPro1595 in Alzheimer’s disease, which is expected to commence this year Boca Raton, FL, July 19, 2021 (GLOBE NEWSWIRE) --...
INMUNE BIO, INC. ANNOUNCES $40 MILLION REGISTERED DIRECT OFFERING
14 juil. 2021 09h02 HE
|
INmune Bio, Inc.
Boca Raton, FL., July 14, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune Bio”), a clinical-stage immunology company focused on developing treatments that harness...
INmune Bio, Inc. Announces First Patient Treated with NK cell priming “pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS)
12 juil. 2021 08h00 HE
|
INmune Bio, Inc.
Boca Raton, FL, July 12, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution
14 juin 2021 16h01 HE
|
INmune Bio, Inc.
Purchase of Xencor Option potentially eliminates approximately 2.1 million shares of INmune future common stock dilution upon execution. LA JOLLA, Calif, June 14, 2021 (GLOBE NEWSWIRE) -- ...
INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USAN
02 juin 2021 09h00 HE
|
INmune Bio, Inc.
LA JOLLA, Calif, June 02, 2021 (GLOBE NEWSWIRE) -- -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021
24 mai 2021 09h00 HE
|
INmune Bio, Inc.
LA JOLLA, Calif, May 24, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update
05 mai 2021 16h15 HE
|
INmune Bio, Inc.
LA JOLLA, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5
28 avr. 2021 09h00 HE
|
INmune Bio, Inc.
LA JOLLA, Calif, April 28, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a...